Bosch F et al. Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): Final results of a multicenter Phase II trial on behalf of the Spanish CLL Study Group (GELLC). Proc ASH 2011;Abstract 293.

Dr Gregory is the Elodia Kehm Chair of Hematology, Professor of Medicine and Director of the Hematology Section at Rush University Medical Center in Chicago, Illinois.

Dr Friedberg is Associate Professor of Medicine and Hematology and Chief of the Hematology/Oncology Division of the James P Wilmot Cancer Center at the University of Rochester in Rochester, New York.